Meta-Analysis of Relation Between Oral [beta]-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention

• Published in: The American journal of cardiology Vol. 115; no. 11; p. 1529
• Main Authors: Huang, Bao-Tao, Huang, Fang-Yang, Zuo, Zhi-Liang, Liao, Yan-Biao, Heng, Yue, Wang, Peng-Ju, Gui, Yi-Yue, Xia, Tian-Li, Xin, Zhe-Mei, Liu, Wei, Zhang, Chen, Chen, Shi-Jian, Pu, Xiao-Bo, Chen, Mao, Huang, De-Jia
• Format: Journal Article
• Language: English
• Published: New York Elsevier Limited 01.06.2015
• Subjects: Angioplasty; Coronary vessels; Heart attacks; Meta-analysis; Studies
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2015.02.057

The aim of the present review was to investigate the association between the use of oral β-blockers and prognosis in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) treatment. A systematic literature search was conducted in Pubmed (from inception to September 27, 2014) and Embase (Ovid SP, from 1974 to September 29, 2014) to identify studies that compared the outcome of patients with AMI taking oral β-blockers with that of patients not taking after PCI. Systematic review and meta-analysis were performed with random-effects model or fixed-effects model. Ten observational studies with a total of 40,873 patients were included. Use of β-blockers was associated with a reduced risk of all-cause death (unadjusted relative risk 0.58, 95% confidential interval 0.48 to 0.71; adjusted hazard ratio 0.76, 95% confidential interval 0.62 to 0.94). The potential benefit of β-blockers in preventing all-cause death was not similar in all population but was restricted to those with reduced ejection fraction, with low use proportion of other secondary prevention drugs or with non-ST-segment elevation myocardial infarction. The association between the use of β-blockers and improved survival rate was significant in <=1-year follow-up duration. Rates of cardiac death, myocardial infarction, and heart failure readmission in patients using β-blockers were not significantly different from those in patients without β-blocker therapy. In conclusion, there is lack of evidence to support routine use of β-blockers in all patients with AMI who underwent PCI. Further trials are urgently needed to address the issue.